• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Evoke Pharma Inc.

    5/15/25 3:51:53 PM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVOK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Evoke Pharma Inc

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    30049G302

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    30049G302


    1Names of Reporting Persons

    Lytton, Laurence W.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    61,274.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    61,274.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    61,274.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares of the Common Stock reported herein consist of warrants to purchase 61,274 shares of Common Stock. The percentages reported in this Schedule 13G are based on 1,492,858 shares of Common Stock outstanding as of May 1, 2025, as reported in the Form 10-Q filed by the Issuer on May 13, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Evoke Pharma Inc
    (b)Address of issuer's principal executive offices:

    420 Stevens Avenue, Suite 370, Solana Beach, CA 92075
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton
    (b)Address or principal business office or, if none, residence:

    467 Central Park West New York, NY 10025
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    30049G302
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    61,274.00
    (b)Percent of class:

    3.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    61,274.00

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    61,274.00

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Lytton, Laurence W.
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:Reporting person
    Date:05/15/2025
    Get the next $EVOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EVOK
    SEC Filings

    See more
    • Evoke Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Evoke Pharma Inc (0001403708) (Filer)

      5/22/25 4:30:21 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Evoke Pharma Inc.

      SCHEDULE 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      5/15/25 3:51:53 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Evoke Pharma Inc.

      10-Q - Evoke Pharma Inc (0001403708) (Filer)

      5/13/25 4:20:20 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 1:08:23 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 9:19:50 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Evoke Pharma Inc.

      SC 13D/A - Evoke Pharma Inc (0001403708) (Subject)

      11/6/24 4:31:54 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

      SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commer

      2/24/25 8:30:37 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

      SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024.   This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management. Mr. Smeal brings extensive experience in investment management and corporate governance. Before transitioning to full-time private investing, he held roles at Willett Advisors, the family office of Michael R. Bl

      10/22/24 8:30:15 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

      SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer. "Working closely with Dave has been an absolute privilege," said Matt D'Onofrio, incoming Chief Executive Officer of Evoke Pharma. "His relentless leadership resulted in our company developing and launchi

      3/21/24 4:15:59 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIMOTI

      Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

      1/15/21 5:10:35 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Financials

    Live finance-specific insights

    See more

    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

      SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 267-6316 and (203) 518-9783 for international callers. The conference ID number is EVOKQ424.

      3/6/25 8:30:28 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

      GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantly enhanced outcomes for patients on GLP-1 therapy, marking it as a promising supportive care option compared to oral metoclopramide. SOLANA BEACH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (met

      11/7/24 4:05:52 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "We're pleased to report continued strong revenue growth in the first quarter of 2025," said Matt D'Onofrio, Chief Executive Officer of Evoke Pharma, Inc. "Net product sales rose 77% year-over-year, underscoring the strengt

      5/13/25 4:05:56 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

      SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. The analysis leverages real-world data from over 100 million U.S. patients and highlights differences in TD incidence rates and timing based on metoclopramide dosing patterns. "This

      4/28/25 8:30:48 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hill Malcolm R

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:28 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd C

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:29 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Garner Cam L

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:24 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care